Stepwise progress

After six years and four Phase I trials ImmusanT Inc. has finally nailed down the optimal dose regimen for celiac disease vaccine Nexvax2 and is ready to take the leap into Phase IIb testing with its $40 million series C round.

New investor Arch Venture Partners led the round and was joined by existing investor Vatera Healthcare Partners. ...